Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors

被引:19
作者
Kong, Moonkyoo
Hong, Seong Eon [1 ]
Choi, Woo Suk [2 ]
Kim, Si-Young [3 ]
Choi, Jinhyun
机构
[1] Kyung Hee Univ, Med Ctr, Dept Radiat Oncol, Sch Med, Seoul 130701, South Korea
[2] Kyung Hee Univ, Sch Med, Dept Diagnost Radiol, Seoul 130701, South Korea
[3] Kyung Hee Univ, Sch Med, Dept Internal Med, Seoul 130701, South Korea
来源
CANCER RESEARCH AND TREATMENT | 2012年 / 44卷 / 02期
关键词
Rectal neoplasms; Preoperative care; Chemoradiotherapy; Pathologic complete response; PATHOLOGICAL COMPLETE RESPONSE; TOTAL MESORECTAL EXCISION; COMBINED-MODALITY THERAPY; NEOADJUVANT CHEMORADIATION; IMPROVED SURVIVAL; RADIOTHERAPY; MANAGEMENT; RADIOCHEMOTHERAPY; CHEMOTHERAPY; RECURRENCE;
D O I
10.4143/crt.2012.44.2.104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response. Materials and Methods From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival. Results The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5-and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%, 95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage. Conclusion Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.
引用
收藏
页码:104 / 112
页数:9
相关论文
共 25 条
[1]  
[Anonymous], N ENGL J MED
[2]   Chemotherapy with preoperative radiotherapy in rectal cancer [J].
Bosset, Jean-Francois ;
Collette, Laurence ;
Calais, Gilles ;
Mineur, Laurent ;
Maingon, Philippe ;
Radosevic-Jelic, Ljiljana ;
Daban, Alain ;
Bardet, Etienne ;
Beny, Alexander ;
Ollier, Jean-Claude .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) :1114-1123
[3]   Preoperative radiotherapy for resectable rectal cancer -: A meta-analysis [J].
Cammà, C ;
Giunta, M ;
Fiorica, F ;
Pagliaro, L ;
Craxì, A ;
Cottone, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (08) :1008-1015
[4]   Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer [J].
Coco, C ;
Valentini, V ;
Manno, A ;
Mattana, C ;
Verbo, A ;
Cellini, N ;
Gambacorta, MA ;
Covino, M ;
Mantini, G ;
Miccichè, F ;
Pedretti, G ;
Petito, L ;
Rizzo, G ;
Cosimelli, M ;
Impiombato, FA ;
Picciocchi, A .
DISEASES OF THE COLON & RECTUM, 2006, 49 (03) :311-318
[5]   A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision [J].
García-Aguilar, J ;
de Anda, EH ;
Sirivongs, P ;
Lee, SH ;
Madoff, RD ;
Rothenberger, DA .
DISEASES OF THE COLON & RECTUM, 2003, 46 (03) :298-304
[6]   Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:: Results of FFCD 9203 [J].
Gerard, Jean-Pierre ;
Conroy, Thierry ;
Bonnetain, Franck ;
Bouche, Olivier ;
Chapet, Olivier ;
Closon-Dejardin, Marie-Therese ;
Untereiner, Michel ;
Leduc, Bernard ;
Francois, Eric ;
Maurel, Jean ;
Seitz, Jean-Francois ;
Buecher, Bruno ;
Mackiewicz, Remy ;
Ducreux, Michel ;
Bedenne, Laurent .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4620-4625
[7]   Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma [J].
Grann, A ;
Feng, C ;
Wong, D ;
Saltz, L ;
Paty, PP ;
Guillem, JG ;
Cohen, AM ;
Minsky, BD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (04) :987-995
[8]   Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer [J].
Guillem, JG ;
Chessin, DB ;
Cohen, AM ;
Shia, J ;
Mazumdar, M ;
Enker, W ;
Paty, PB ;
Weiser, MR ;
Klimstra, D ;
Saltz, L ;
Minsky, BD ;
Wong, WD .
ANNALS OF SURGERY, 2005, 241 (05) :829-838
[9]   Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy [J].
Habr-Gama, A. .
COLORECTAL DISEASE, 2006, 8 :21-24
[10]   Non-operative management of rectal cancer after neoadjuvant chemoradiation [J].
Habr-Gama, A. ;
Perez, R. O. .
BRITISH JOURNAL OF SURGERY, 2009, 96 (02) :125-127